Delayed but not early treatment with dnase reduces organ damage and improves outcome in a murine model of sepsis

Shock

Volumn 44, Issue 2, 2015, Pages 166-172

  Mai, Safiah H C ^a   Khan, Momina ^a   Dwivedi, Dhruva J ^a,b   Ross, Catherine A ^c   Zhou, Ji ^a   Gould, Travis J ^a   Gross, Peter L ^a,b   Weitz, Jeffrey I ^a,b   Fox Robichaud, Alison E ^a,b   Liaw, Patricia C ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b Departments of Medicine   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Coagulation; Deoxyribonucleases; Inflammation; Multiple organ failure; Sepsis; Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; DEOXYRIBONUCLEASE; INTERLEUKIN 10; INTERLEUKIN 6; MYELOPEROXIDASE; THROMBIN ANTITHROMBIN COMPLEX; ANTIINFECTIVE AGENT; ANTITHROMBIN; DNA; IL10 PROTEIN, MOUSE; INTERLEUKIN-6, MOUSE; PEROXIDASE; THROMBIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL LOAD; CECAL LIGATION AND PUNCTURE-INDUCED SEPSIS; CONTROLLED STUDY; DEATH; ENZYME ACTIVITY; HISTOPATHOLOGY; MALE; MOUSE; NEUTROPHIL; NONHUMAN; ORGAN INJURY; TREATMENT RESPONSE; ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; DRUG ADMINISTRATION; ENZYMOLOGY; INFLAMMATION; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG; METABOLISM; MULTIPLE ORGAN FAILURE; SEPSIS; TIME FACTOR;

ALANINE TRANSAMINASE; ANIMALS; ANTI-INFECTIVE AGENTS; ANTITHROMBINS; CREATININE; DEOXYRIBONUCLEASES; DISEASE MODELS, ANIMAL; DNA; DRUG ADMINISTRATION SCHEDULE; INFLAMMATION; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-10; INTERLEUKIN-6; LUNG; MALE; MICE; MICE, INBRED C57BL; MULTIPLE ORGAN FAILURE; PEROXIDASE; SEPSIS; THROMBIN; TIME FACTORS;

EID: 84942579500     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000396     Document Type: Article

References (35)

1. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, et al.: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41:580-637, 2013.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310, 2001.
3. Wang HE, Shapiro NI, Griffin R, Safford MM, Judd S, Howard G: Chronic medical conditions and risk of sepsis. PLoS One 7:e48307, 2012.
4. Marshall JC: Why have clinical trials in sepsis failed? Trends Mol Med 20:195-203, 2014.
5. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A: Neutrophil extracellular traps kill bacteria. Science 303:1532-1535, 2004.
6. Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A: Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol 191:677-691, 2010.
7. Ammollo CT, Semeraro F, Xu J, Esmon NL, Esmon CT: Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation. J Thromb Haemost 9:1795-1803, 2011.
8. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD Jr., Wrobleski SK, Wakefield TW, Hartwig JH, Wagner DD: Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 107:15880-15885, 2010.
9. Semeraro F, Ammollo CT, Morrissey JH, Dale GL, Friese P, Esmon NL, Esmon CT: Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood 118:1952-1961, 2011.
10. MengW, Paunel-GörgülüA, Flohé S, Hoffmann A, Witte I, MacKenzie C, Baldus SE, Windolf J, Lögters TT: Depletion of neutrophil extracellular traps in vivo results in hypersusceptibility to polymicrobial sepsis in mice. Crit Care 16:R137, 2012.
11. Zeerleder S, Zwart B, Wuillemin WA, Aarden LA, Groeneveld AB, Caliezi C, van Nieuwenhuijze AE, van Mierlo GJ, Eerenberg AJ, Lämmle B, et al.: Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med 31:1947-1951, 2003.
12. Dwivedi DJ, Toltl LJ, Swystun LL, Pogue J, Liaw KL, Weitz JI, Cook DJ, Fox-Robichaud AE, Liaw PC, Canadian Critical Care Translational Biology Group: Prognostic utility and characterization of cell-free DNA in patients with severe sepsis. Crit Care 16:R151, 2012.
13. Gould TJ, Vu TT, Swystun LL, Dwivedi DJ, Mai SH, Weitz JI, Liaw PC: Neutrophil extracellular traps promote thrombin generation through plateletdependent and platelet-independent mechanisms. Arterioscler Thromb Vasc Biol 34:1977-1984, 2014.
14. Meng W, Paunel-GörgülüA, Flohé S, Witte I, Schädel-Höpfner M, Windolf J, Lögters TT: Deoxyribonuclease is a potential counter regulator of aberrant neutrophil extracellular traps formation after major trauma. Mediators Inflamm 2012:149560, 2012.
15. Prince WS, Baker DL, Dodge AH, Ahmed AE, Chestnut RW, Sinicropi DV: Pharmacodynamics of recombinant human DNase I in serum. Clin Exp Immunol 113:289-296, 1998.
16. Shak S: Aerosolized recombinant human DNase I for the treatment of cystic fibrosis. Chest 107(2 Suppl):65SY70S, 1995.
17. Rahman NM, Maskell NA, West A, Teoh R, Arnold A, Mackinlay C, Peckham D, Davies CW, Ali N, Kinnear W, et al.: Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med 365:518-526, 2011.
18. Luo L, Zhang S, Wang Y, Rahman M, Syk I, Zhang E, Thorlacius H: Proinflammatory role of neutrophil extracellular traps in abdominal sepsis. Am J Physiol Lung Cell Mol Physiol 307(7):L586YL596, 2014. Available at: http://ajplung.physiology.org/content/307/7/L586. Accessed February 27, 2015.
19. Baker CC, Chaudry IH, Gaines HO, Baue AE: Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 94:331-335, 1983.
20. Hubbard WJ, Choudhry M, Schwacha MG, Kerby JD, Rue LW 3rd, Bland KI, Chaudry IH: Cecal ligation and puncture. Shock 24(Suppl 1):52-57, 2005.
21. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG: Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. Osteoarthritis Cartilage 20:256-260, 2012.
22. Mai S, Khan M, Liaw P, Fox-Robichaud A: Experimental sepsis models. In: SepsisVAn Ongoing and Significant Challenge. Azevedo L (ed.). 2012. Available at: http://www.intechopen.com/books/sepsis-An-ongoing-And-significantchallenge/experimental-sepsis-modelspdf. Accessed November 13, 2014.
23. Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer AJ, Thijs LG, Aarden LA: Increased plasma levels of interleukin-6 in sepsis. Blood 74:1704-1710, 1989.
24. Remick DG, Bolgos G, Copeland S, Siddiqui J: Role of interleukin-6 in mortality from and physiologic response to sepsis. Infect Immun 73:2751-2757, 2005.
25. Remick DG, Newcomb DE, Bolgos GL, Call DR: Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 13:110-116, 2000.
26. Tucker EI, Verbout NG, Leung PY, Hurst S, McCarty OJ, Gailani D, Gruber A: Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis. Blood 119:4762-4768, 2012.
27. Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, Cariou A, Um SL, Utterback B, Laterre PF, Dhainaut JF, et al.: Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit Care R82YR90, 2004.
28. Dayan AD: Pharmacological-toxicological expert report on recombinant human deoxyribonuclease I (rhDNase; Pulmozyme). Hum Exp Toxicol 13:S2-S42, 1994.
29. Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, Patel KD, Chakrabarti S, McAvoy E, Sinclair GD, et al.: Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 13:463-469, 2007.
30. McDonald B, Urrutia R, Yipp BG, Jenne CN, Kubes P: Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis. Cell Host Microbe 12:324-333, 2012.
31. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, Early Goal-Directed Therapy Collaborative Group: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368-1377, 2001.
32. ProCESS Investigators, Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, Pike F, Terndrup T, Wang HE, Hou PC, et al.: A randomized trial of protocolbased care for early septic shock. N Engl J Med 370:1683-1693, 2014.
33. Vincent JL, Gerlach H: Fluid resuscitation in severe sepsis and septic shock: an evidence-based review. Crit Care Med 32(11 Suppl):S451-S454, 2004.
34. Suri R, Marshall LJ, Wallis C, Metcalfe C, Bush A, Shute JK: Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. Am J Respir Crit Care Med 166:352-355, 2002.
35. Shah PL, Scott SF, Knight RA, Marriott C, Ranasinha C, Hodson ME: In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis. Thorax 51:119-125, 1996.